ArticleRadiation oncology journal2026
Clinical utility of endorectal balloons in prostate cancer external beam radiotherapy: a systematic review and meta-analysis.
Article in Radiation oncology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
purposeThis study aimed to systematically evaluate the clinical utility of endorectal balloons (ERB) for motion management and organ-at-risk sparing in prostate cancer patients receiving external beam radiotherapy (EBRT) or stereotactic body radiotherapy (SBRT). MATERIALS AND
methodsA systematic search was conducted in Ovid MEDLINE, Embase, the Cochrane Library, and Korean databases through May 8, 2024. Primary outcomes included safety, toxicity, prostate motion, and dosimetric parameters. The risk of bias was assessed using the Risk of Bias Assessment tool for Non-randomized Studies 2.0 tools. Meta-analysis was conducted using Review Manager 5.3.
resultsTwenty-seven studies (3 prospective cohort studies, 24 retrospective studies) were included, covering 22 EBRT and 5 SBRT cohorts. Reported adverse events were mild and transient. One prospective study demonstrated a significant reduction in grade 1 late rectal toxicity (p = 0.003). ERB use significantly stabilized the prostate, reducing both intra- and interfractional motion, particularly minimizing displacements >5 mm. Meta-analysis revealed that ERB significantly lowered the mean radiation dose to the rectum (mean difference [MD], -3.40 Gy; 95% confidence interval [CI], -6.70 to -0.10) and anal wall (MD, -6.06 Gy; 95% CI, -9.78 to -2.35) in EBRT. Similarly, in SBRT, ERB was associated with reduced rectal wall dose (MD, -2.63 Gy; 95% CI, -4.49 to -0.77).
conclusionERB appears to be a relatively safe and clinically useful adjunct for enhancing treatment precision in prostate cancer radiotherapy. By stabilizing prostate motion and reducing radiation exposure to the rectum and anal wall, ERB optimizes the therapeutic ratio.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.